Enanta Pharmaceuticals Inc
ENTA7.040USD
-0.070-0.98%
交易中 （美東）報價延遲15分鐘
150.49M總市值
虧損本益比TTM
關於 Enanta Pharmaceuticals Inc 公司
Enanta Pharmaceuticals, Inc. 是一家臨牀階段的生物技術公司。該公司從事小分子藥物的發現和開發，重點是病毒學和免疫學的適應症。該公司的臨牀項目專注於呼吸道合胞病毒 (RSV)，其早期免疫學管線旨在通過針對 2 型免疫反應的關鍵驅動因素（包括受體酪氨酸激酶 (KIT) 和 STAT6 抑制）來開發炎症性疾病的治療方法。該公司有兩種針對 RSV 的臨牀階段候選產品，分別是澤利卡帕韋和 EDP-323。該公司發現的蛋白酶抑制劑 Glecaprevir 是治療慢性丙型肝炎病毒 (HCV) 感染的治療方案之一，由 AbbVie 在多個國家以商品名 MAVYRET（美國）和 MAVIRET（美國以外）（glecaprevir/pibrentasvir）銷售。該公司還擁有針對 SARS-CoV-2 和乙肝病毒的病毒學開發項目。
公司簡介
公司代碼ENTA
公司名稱Enanta Pharmaceuticals Inc
上市日期Mar 21, 2013
CEODr. Jay R. Luly, Ph.D.
員工數量131
證券類型Ordinary Share
年結日Mar 21
公司地址4 Kingsbury Avenue
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話16176070800
網址https://www.enanta.com/
公司代碼ENTA
上市日期Mar 21, 2013
CEODr. Jay R. Luly, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
收入明細
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
14.93M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
持股股東
持股股東
佔比
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
股東類型
持股股東
佔比
Investment Advisor
35.82%
Hedge Fund
25.06%
Investment Advisor/Hedge Fund
23.43%
Individual Investor
6.69%
Research Firm
2.01%
Bank and Trust
0.30%
Family Office
0.20%
Sovereign Wealth Fund
0.19%
Pension Fund
0.15%
Other
6.14%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
315
20.05M
93.80%
-6.87M
2025Q1
342
20.11M
94.09%
-7.55M
2024Q4
348
21.38M
100.27%
-5.34M
2024Q3
354
22.65M
106.92%
-6.74M
2024Q2
352
23.60M
111.43%
-6.27M
2024Q1
361
24.29M
114.84%
-4.07M
2023Q4
373
21.96M
104.28%
-4.11M
2023Q3
375
22.04M
104.75%
-4.91M
2023Q2
376
21.98M
104.47%
-3.80M
2023Q1
380
21.64M
103.62%
-3.43M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Farallon Capital Management, L.L.C.
2.12M
9.93%
+14.00K
+0.66%
Mar 31, 2025
Krensavage Asset Management, LLC
2.12M
9.9%
-804.00
-0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.01M
9.39%
+23.27K
+1.17%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
8.05%
+3.27K
+0.19%
Mar 31, 2025
Millennium Management LLC
1.35M
6.3%
-35.34K
-2.56%
Mar 31, 2025
Acadian Asset Management LLC
867.04K
4.06%
+17.61K
+2.07%
Mar 31, 2025
Marshall Wace LLP
850.89K
3.98%
-79.20K
-8.52%
Mar 31, 2025
Luly (Jay R)
826.73K
3.87%
+62.57K
+8.19%
Feb 12, 2025
Stonepine Capital Management, LLC
590.74K
2.76%
+258.84K
+77.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
494.20K
2.31%
+16.97K
+3.56%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Avantis US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.57%
iShares Micro-Cap ETF
佔比0.03%
Vanguard US Value Factor ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
